Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Common Equity (2016 - 2025)

Rocket Pharmaceuticals' Common Equity history spans 10 years, with the latest figure at $277.2 million for Q4 2025.

  • For Q4 2025, Common Equity fell 40.16% year-over-year to $277.2 million; the TTM value through Dec 2025 reached $277.2 million, down 40.16%, while the annual FY2025 figure was $277.2 million, 40.16% down from the prior year.
  • Common Equity for Q4 2025 was $277.2 million at Rocket Pharmaceuticals, down from $313.7 million in the prior quarter.
  • Across five years, Common Equity topped out at $541.1 million in Q3 2023 and bottomed at $277.2 million in Q4 2025.
  • The 5-year median for Common Equity is $429.6 million (2022), against an average of $422.2 million.
  • The largest annual shift saw Common Equity surged 100.82% in 2021 before it plummeted 40.16% in 2025.
  • A 5-year view of Common Equity shows it stood at $454.7 million in 2021, then grew by 7.69% to $489.7 million in 2022, then rose by 0.59% to $492.6 million in 2023, then fell by 5.96% to $463.2 million in 2024, then tumbled by 40.16% to $277.2 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Common Equity are $277.2 million (Q4 2025), $313.7 million (Q3 2025), and $354.2 million (Q2 2025).